3.4.11.18: methionyl aminopeptidase
This is an abbreviated version!
For detailed information about methionyl aminopeptidase, go to the full flat file.
Word Map on EC 3.4.11.18
-
3.4.11.18
-
microtubule-associated
-
microtubule
-
dendritic
-
hippocampus
-
tubulin
-
protein-2
-
tau
-
cerebral
-
aminopeptidases
-
fumagillin
-
nestin
-
neurite
-
cortical
-
cytoskeletal
-
neurofilament
-
neuroprotective
-
ischemia
-
fibrillary
-
synaptophysin
-
outgrowth
-
neurotrophic
-
neuron-specific
-
beta-tubulin
-
neurogenesis
-
map2
-
synapsin
-
antiangiogenic
-
deformylase
-
microtubule-binding
-
calbindin
-
synthesis
-
dinuclear
-
microsporidian
-
drug development
-
medicine
- 3.4.11.18
-
microtubule-associated
- microtubule
- dendritic
- hippocampus
- tubulin
- protein-2
- tau
- cerebral
- aminopeptidases
- fumagillin
- nestin
-
neurite
- cortical
- cytoskeletal
- neurofilament
-
neuroprotective
- ischemia
-
fibrillary
-
synaptophysin
-
outgrowth
-
neurotrophic
-
neuron-specific
- beta-tubulin
-
neurogenesis
- map2
- synapsin
-
antiangiogenic
-
deformylase
-
microtubule-binding
- calbindin
- synthesis
-
dinuclear
-
microsporidian
- drug development
- medicine
Reaction
release of N-terminal amino acids, preferentially methionine, from peptides and arylamides =
Synonyms
aminopeptidase, methionine, c1MetAP-Ia, c2MetAP-Ia, c3MetAP-Ib, CoCoEcMetAP, Ebp1, eMet-AP, ErbB-3 receptor binding protein, initiation factor 2 associated 67 kDa glycoprotein, L-methionine aminopeptidase, LdBPK_210960, MAP, MAP-2, MAP-Pfu, MAP11, MAP1D, mAPA, MapB, MetAP, MetAP-1, MetAP-2, MetAP-I, MetAP-II, MetAP1, MetAP1a, MetAP1b, MetAP1c, MetAP1D, MetAP2, methionine amino peptidase type 2, methionine aminopeptidase, methionine aminopeptidase 1, methionine aminopeptidase 1b, methionine aminopeptidase 2, methionine aminopeptidase AbMetAPx, methionine aminopeptidase AbMetAPy, methionine aminopeptidase II, methionine aminopeptidase type 1, methionine aminopeptidase type 1a, methionine aminopeptidase type 1c, methionine aminopeptidase type 2, methionine aminopeptidase type I, methionine aminopeptidase type II, methionine aminopeptidase type-2, methionine aminopeptidase-1, methionine aminopeptidase-2, methionine aminopetidase-2, More, p67, p67eIF2, peptidase M, PVX_094985, TM1478, type 1 methionine aminopeptidase, type 2 methionine aminopeptidase, type I MetAP, type I methionine aminopeptidase, YpdF
ECTree
3.4.11.18 methionyl aminopeptidaseAdvanced search results
results (
results (Inhibitors
Inhibitors on EC 3.4.11.18 - methionyl aminopeptidase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
INHIBITOR 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
(2E,4E,6E,8E)-10-((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yloxy)-10-oxodeca-2,4,6,8-tetraenoic acid
-
-
(2R,3R,4S,5R,E)-3,4,5-trihydroxy-N-[(1-isobutyrylpiperidin-3-yl)-methyl]-2-methoxy-8,8-dimethylnon-6-enamide
-
-
(2R,3R,4S,5R,E)-3,4,5-trihydroxy-N-[2-(mesityloxy)ethyl]-2-methoxy-8,8-dimethylnon-6-enamide
-
-
(2R,3R,4S,5R,E)-N-(2,3-dihydro-1H-inden-2-yl)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide
-
-
(2R,3R,4S,5R,E)-N-(2-amino-2-oxoethyl)-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide
-
-
(2R,3R,4S,5R,E)-N-[3-(4-fluorophenyl)-3-(furan-2-yl)propyl]-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide
-
-
(2R,3R,4S,5R,E)-N-[3-(furan-2-yl)-3-phenylpropyl]-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide
-
-
(2R,3R,4S,5R,E)-N-[[1-(cyclopropanecarbonyl)piperidin-3-yl]methyl]-3,4,5-trihydroxy-2-methoxy-8,8-dimethylnon-6-enamide
-
-
(3E)-3-(furan-2-ylmethylidene)-5-(hydroxymethyl)-1-methoxy-6-[2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]bicyclo[3.1.0]hexan-2-one
no activity at 0.1 mM
(3R)-amino-(2S)-hydroxypentanoic acid
-
IC50: 0.0123 mM for the Co2+-substituted enzyme, 0.0115 mM for the Mn2+-substituted enzyme, 0.0093 mM for the Zn2+-substituted enzyme, 0.0223 for the Ni2+-substituted enzyme
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-ol
-
-
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl (2R)-3-methyl-1-(2-(1-methylpyrrolidin-2-yl)ethylamino)-1-oxobutan-2-ylcarbamate
-
-
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl (R)-1-amino-3-methyl-1-oxobutan-2-yl carbamate
-
i.e. PPI-2458, advanced into phase I clinical studies in non-Hodgkin's lymphoma and solid cancers, overview
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl (R)-1-amino-3-methyl-1-oxobutan-2-ylcarbamate
-
-
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl (R)-1-hydroxy-3-methylbutan-2-ylcarbamate
-
-
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl (R)-3-methyl-1-(morpholinoamino)-1-oxobutan-2-ylcarbamate
-
-
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl (R)-3-methyl-1-oxo-1-(2-(pyrrolidin-1-yl)ethylamino)butan-2-ylcarbamate
-
-
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl 1-amino-2-methyl-1-oxopropan-2-ylcarbamate
-
-
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl 1-carbamoylcyclopentylcarbamate
-
-
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl 2-(1-methylpyrrolidin-2-yl)ethylcarbamate
-
-
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl 2-(pyrrolidin-1-yl)ethylcarbamate
-
-
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl isopropylcarbamate
-
-
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl morpholinocarbamate
-
-
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl tert-butylcarbamate
-
-
(3R,5S,6R)-5-methoxy-4-[(3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]oct-6-yl (chloroacetyl)carbamate
-
-
(5,5-Dimethyl-4,5-dihydro-thiazol-2-yl)-(3-methyl-pyridin-2-yl)-amine
-
IC50 for Co-EcMetAP1: 0.00021 mM
(8S)-2-[[(4-fluorophenyl)sulfonyl]amino]-8-methyl-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid
-
(R)-methyl 2-(((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yloxy)carbonylamino)-2-phenylacetate
-
-
(R)-methyl 2-(((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yloxy)carbonylamino)-3-methylbutanoate
-
-
(R)-methyl 2-(((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yloxy)carbonylamino)-4-methylpentanoate
-
-
(S)-methyl 2-(((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yloxy)-carbonylamino)-3-methylbutanoate
-
-
1-(((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yloxy)carbonyl)-piperidine-4-carboxylic acid
-
-
1-(5-chloro-6-methyl-2-pyridin-2-yl-3,4-dihydropyrimidin-4-yl)-2-(2-sulfanylmorpholin-4-yl)ethanone
-
-
1-(5-chloro-6-methyl-2-pyridin-2-yl-3,4-dihydropyrimidin-4-yl)-2-(2-sulfanylphenyl)ethanone
-
-
1-(5-chloro-6-methyl-2-pyridin-2-yl-3,4-dihydropyrimidin-4-yl)-2-(4-fluoro-2-sulfanylphenyl)ethanone
-
-
1-(5-chloro-6-methyl-2-pyridin-2-yl-3,4-dihydropyrimidin-4-yl)-2-(4-methoxy-2-sulfanylphenyl)ethanone
-
-
1-(5-chloro-6-methyl-2-pyridin-2-ylpyrimidin-4-yl)-4-(2,4-dichlorobenzyl)-1,4-diazepane
-
1-benzyl-2-pyridin-2-yl-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00099 mM
1-methoxy-5-(methoxymethyl)-6-[2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]bicyclo[3.1.0]hexan-2-one
no activity at 0.1 mM
1-[2-pyridin-2-yl-6-(trifluoromethyl)-3,4-dihydropyrimidin-4-yl]propane-2-thiol
-
-
2,2'-bipyridine
-
maximum inhibition is observed in the presence of CoCl2 rather than other metal ions
2-((1,3-thiazol-2-ylamino)carbonyl)pyridin-3-yl phenylacetate
-
Co(II)-form of enzyme, 50% inhibition at 0.00046 mM
2-((1H-1,2,4-triazol-5-ylthio)methyl)benzonitrile
-
Co(II)-form of enzyme, 50% inhibition at 0.00066 mM
2-(1,3-thiazol-4-yl)-1H-imidazo(4,5-c)pyridine
Co(II)-form of enzyme, 50% inhibition at 0.00172 mM
2-(1H-benzimidazol-2-ylamino)pyridin-3-ol
Co(II)-form of enzyme, 50% inhibition at 0.00078 mM
2-(2-(((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yloxy)-carbonylamino)ethyl)-1,1-dimethylpyrrolidinium iodide
-
-
2-(2-aminoethoxy)-3-ethyl-6-[[(2-propylphenyl)sulfonyl]amino]benzoic acid
-
2-(2-aminoethoxy)-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid
-
2-(2-aminoethoxy)-6-[([2-[3-(diethylamino)propyl]-4-fluorophenyl]sulfonyl)amino]-3-ethylbenzoic acid
-
2-(3H-pyrrol-5-yl)-1H-imidazo(4,5-b)pyridine
Co(II)-form of enzyme, 50% inhibition at 0.000078 mM
2-(5-methoxy-6-[2-methyl-3-((3-methylbut-2-en-1-yl)oxiran-2-yl]-4-oxobicyclo[3.1.0]hex-1-yl)methyl)-1H-isoindole-1,3(2H)-dione
no activity at 0.1 mM
2-(carboxymethoxy)-3-ethyl-6-[[(4-fluorophenyl)sulfonyl]amino]benzoic acid
-
2-({3-[3,5-bis[4-nitrobenzylidene]-4-oxopiperidin-1-yl]-3-oxopropylsulfanyl) ethanesulfonic acid
-
inhibitor of MetAP2
2-amino-4-(methylthio)-1-(1,3-thiazol-2-yl)butan-1-one
50% inhibition at 0.019 mM, formation of uncleavable tetrahedral intermediate upon binding
2-amino-4-(methylthio)-1-pyridin-2-ylbutan-1-one
50% inhibition at 0.016 mM, formation of uncleavable tetrahedral intermediate upon binding
2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone
-
inhibitor of HIV-1 replication and transcription, and potent and selective inhibitor of isoforms MetAP1a and MetAP1c. The inhibitor is active against replicating and aged non-growing Micobacterium tuberculosis at low micromolar concentrations
2-hydroxyethyl disulfide
inhibition is through covalent modifiction of residue C105
2-pyridin-2-yl-1H-benzimidazol-5-amine
Co(II)-form of enzyme, 50% inhibition at 0.0097 mM
2-pyridin-2-yl-1H-benzimidazole-5-carbonitrile
Co(II)-form of enzyme, 50% inhibition at 0.00043 mM
2-pyridin-2-yl-1H-imidazo(4,5-b)pyrazine
Co(II)-form of enzyme, 50% inhibition at 0.00024 mM
2-pyridin-2-yl-1H-imidazo(4,5-b)pyridine
Co(II)-form of enzyme, 50% inhibition at 0.00011 mM
2-pyridin-2-yl-1H-imidazo(4,5-c)pyridine
Co(II)-form of enzyme, 50% inhibition at 0.00055 mM
2-pyridin-2-yl-4-(trifluoromethyl)-6-[2-(trifluoromethyl)benzyl]-1,6-dihydropyrimidine
-
-
2-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid
potent inhibitor but lacks cellular activity and is highly protein bound
2-[([4-[(E)-(5-amino-3-imino-3H-pyrazol-4-yl)diazenyl]phenyl]sulfinyl)oxy]hydrazinecarboximidamide
-
-
2-[2-(2-amino-4-methylsulfanyl-butyrylsulfanyl)-3-phenyl-propionylamino]-3-hydroxy-propionic acid
-
IC50 for Co-EcMetAP1: 0.0296 mM, IC50 for Mn-EcMetAPa: 0.0441 mM, IC50 for Zn-EcMetAP1: 0.0365 mM
2-[2-(2-Amino-4-methylsulfanyl-butyrylsulfanyl)-5-methyl-hexanoylamino]-3-hydroxy-propionic acid
-
IC50 for Co-EcMetAP1: 0.0286 mM, IC50 for Mn-EcMetAPa: 0.0443 mM, IC50 for Zn-EcMetAP1: 0.0498 mM, IC50 for Ni-EcMetAP1: 0.0357 mM
2-[2-(3-Amino-2-hydroxy-heptanoylamino)-propionylamino]-4-methyl-pentanoic acid methyl ester
-
IC50 for Co-EcMetAP1: 0.0229 mM, IC50 for Mn-EcMetAPa: 0.0252 mM, IC50 for Zn-EcMetAP1: 0.0167 mM, IC50 for Ni-EcMetAP1: 0.0125 mM
2-[4-(2-Cyano-2-ethoxycarbonyl-1-methyl-vinyl)-phenyl]-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxylic acid
-
IC50 for Co-EcMetAP1: 0.037 mM
2-[[(4-fluorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid
-
2-[[(4-fluorophenyl)sulfonyl]amino]-8-methyl-5,6-dihydronaphthalene-1-carboxylic acid
-
3-(((2-(((1'-methyl-1,4'-bipiperidin-4-yl)methyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000055 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00037 mM
3-(((2-(((1-(1-methylethyl)piperidin-4-yl)methyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000046 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00095 mM
3-(((2-(((1-methylpiperidin-4-yl)methyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000015 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00013 mM
3-(((2-(((2-(diethylamino)ethyl)carbamoyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000017 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00037 mM
3-(((2-((1E)-3-((2-hydroxyethyl)(methyl)amino)prop-1-en-1-yl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000015 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000024 mM
3-(((2-((1E)-3-(4-methylpiperazin-1-yl)prop-1-en-1-yl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000018 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000042 mM
3-(((2-((1E)-3-(diethylamino)but-1-en-1-yl)-4-fluorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000016 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00007 mM
3-(((2-((1E)-3-(diethylamino)but-1-en-1-yl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000019 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00026 mM
3-(((2-((1E)-3-(diethylamino)prop-1-en-1-yl)-4-fluorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000011 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000006 mM
3-(((2-((1E)-3-(diethylamino)prop-1-en-1-yl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000012 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000019 mM; 50% inhibition of enzyme at 0.000027 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00029 mM
3-(((2-((1E)-3-(dimethylamino)prop-1-en-1-yl)-4-fluorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000019 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000036 mM
3-(((2-((1E)-3-(dimethylamino)prop-1-en-1-yl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000017 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000081 mM
3-(((2-((1E)-3-(ethyl(2-hydroxyethyl)amino)but-1-en-1-yl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000015 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000038 mM
3-(((2-((1E)-3-(ethyl(methyl)amino)prop-1-en-1-yl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000009 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000023 mM
3-(((2-((1E)-3-(methyl(1-methylethyl)amino)prop-1-en-1-yl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000012 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000027 mM
3-(((2-((1E)-4-(diethylamino)but-1-en-1-yl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000016 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000049 mM; 50% inhibition of enzyme at 0.000025 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00017 mM
3-(((2-((1E)-5-(diethylamino)pent-1-en-1-yl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000020 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00012 mM; 50% inhibition of enzyme at 0.000028 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000033 mM
3-(((2-((2-(1-(1-methylethyl)pyrrolidin-2-yl)ethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000062 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00035 mM
3-(((2-((2-(1-(1-methylpiperidin-4-yl)pyrrolidin-2-yl)ethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000070 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0005 mM
3-(((2-((2-(1-(cyclohexylmethyl)pyrrolidin-2-yl)ethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.00015 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0015 mM
3-(((2-((2-(1-piperidin-4-ylpyrrolidin-2-yl)ethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000069 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0013 mM
3-(((2-((2-(1H-imidazol-1-yl)ethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000010 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0029 mM
3-(((2-((2-(2-oxopyrrolidin-1-yl)ethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000040 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0014 mM
3-(((2-((2-(bis(1-methylethyl)amino)ethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000031 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00064 mM
3-(((2-((2-(diethylamino)ethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000031 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00054 mM
3-(((2-((2-(diethylamino)ethyl)carbamoyl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000031 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00052 mM
3-(((2-((2-(dimethylamino)ethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000048 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0013 mM
3-(((2-((2-(dimethylamino)ethyl)sulfanyl)-4-fluorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000030 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0007 mM
3-(((2-((2-pyridin-2-ylethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000053 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0020 mM
3-(((2-((2-pyridin-4-ylethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000016 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0085 mM
3-(((2-((2-pyrrolidin-1-ylethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000069 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0022 mM
3-(((2-((2-pyrrolidin-2-ylethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000022 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00014 mM
3-(((2-((3-((2-hydroxyethyl)amino)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000015 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00028 mM
3-(((2-((3-((2-tert-butoxy-2-oxoethyl)amino)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.00011 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0043 mM
3-(((2-((3-((tert-butoxycarbonyl)amino)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000077 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0049 mM
3-(((2-((3-(1,4'-bipiperidin-1'-yl)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000058 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0011 mM
3-(((2-((3-(1-methylpyrrolidin-2-yl)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000017 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000096 mM
3-(((2-((3-(4-methylpiperazin-1-yl)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000026 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00041 mM
3-(((2-((3-(bis(1-methylethyl)amino)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000052 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00029 mM
3-(((2-((3-(bis(2-hydroxyethyl)amino)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000026 mM, 50% inhibition of proliferation of HT-1080 cells at 0.001 mM
3-(((2-((3-(diethylamino)-1-methylpropyl)carbamoyl)-4-fluorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000067 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00012 mM
3-(((2-((3-(diethylamino)-1-methylpropyl)carbamoyl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000017 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0026 mM
3-(((2-((3-(diethylamino)propyl)amino)-4-methylphenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.00015 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0021 mM
3-(((2-((3-(diethylamino)propyl)amino)-5-(trifluoromethyl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.00069 mM, 50% inhibition of proliferation of HT-1080 cells at 0.100 mM
3-(((2-((3-(diethylamino)propyl)amino)-5-methylphenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000066 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00066 mM
3-(((2-((3-(diethylamino)propyl)amino)-6-fluorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000019 mM, 50% inhibition of proliferation of HT-1080 cells at 0.014 mM; 50% inhibition of enzyme at 0.00018 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0083 mM
3-(((2-((3-(diethylamino)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000025 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0014 mM
3-(((2-((3-(diethylamino)propyl)carbamoyl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000025 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00055 mM
3-(((2-((3-(dimethylamino)-2,2-dimethylpropyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000018 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00061 mM
3-(((2-((3-(dimethylamino)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000014 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00019 mM
3-(((2-((3-(ethylamino)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000012 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00011 mM
3-(((2-((3-aminopropyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000013 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00016 mM
3-(((2-((3-morpholin-4-ylpropyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000022 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00032 mM
3-(((2-((3-piperazin-1-ylpropyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000020 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00051 mM
3-(((2-((3-pyrrolidin-1-ylpropyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000017 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000085 mM
3-(((2-((4-(diethylamino)-1-methylbutyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.00013 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00021 mM
3-(((2-((4-(dimethylamino)butyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000012 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00046 mM
3-(((2-((piperidin-3-ylmethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000035 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00029 mM
3-(((2-((piperidin-4-ylmethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000017 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00046 mM
3-(((2-((pyridin-4-ylmethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000035 mM, 50% inhibition of proliferation of HT-1080 cells at 0.017 mM
3-(((2-((pyrrolidin-3-ylmethyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000034 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00038 mM
3-(((2-(3,3,4,5,5-pentamethylpiperazin-1-yl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000091 mM, 50% inhibition of proliferation of HT-1080 cells at 0.015 mM
3-(((2-(3-(diethylamino)propoxy)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000018 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0062 mM
3-(((2-(3-(diethylamino)propyl)-4-fluorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000017 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000024 mM
3-(((2-(3-(diethylamino)propyl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000009 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000073 mM
3-(((2-(3-(dimethylamino)propyl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000010 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000035 mM
3-(((2-(4-(diethylamino)butyl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000019 mM, 50% inhibition of proliferation of HT-1080 cells at 0.000068 mM
3-(((2-(4-benzylpiperazin-1-yl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000020 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0016 mM
3-(((2-(5-(diethylamino)pentyl)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000045 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00035mM
3-(((2-aminophenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000013 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0062 mM
3-(((3-chloro-2-((3-(diethylamino)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000015 mM, 50% inhibition of proliferation of HT-1080 cells at 0.00037 mM
3-(((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yloxy)carbonylamino)-N,N,N-trimethylpropan-1-aminium iodide
-
-
3-(((4-chloro-2-((3-(diethylamino)propyl)amino)-5-fluorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.00079 mM, 50% inhibition of proliferation of HT-1080 cells at 0.013 mM
3-(((4-chloro-2-((3-(diethylamino)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.00011 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0031 mM
3-(((5-chloro-2-((3-(diethylamino)propyl)amino)phenyl)sulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000056 mM, 50% inhibition of proliferation of HT-1080 cells at 0.010 mM
3-((4-methylpent-3-enoyl)amino)-N-1,3-thiazol-2-ylpyridine-2-carboxamide
-
wild-type, 50% inhibition at 0.0149 mM, mutant lacking N-terminal 66 amino acids, 50% inhibition at 0.00068 mM
3-((5-methylhex-4-enoyl)amino)-N-1,3-thiazol-2-ylpyridine-2-carboxamide
-
wild-type, 50% inhibition at 0.0074 mM, mutant lacking N-terminal 66 amino acids, 50% inhibition at 0.0010 mM
3-((cyclopent-1-en-1-ylcarbonyl)amino)-N-1,3-thiazol-2-ylpyridine-2-carboxamide
-
wild-type, 50% inhibition above 100 mM, mutant lacking N-terminal 66 amino acids, 50% inhibition above 100 mM
3-((phenylsulfonyl)amino)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
50% inhibition of enzyme at 0.000010 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0024 mM
3-((R)-2-(((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yloxy)-carbonylamino)-3-methylbutanamido)benzoic acid
-
-
3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-{[(2-nitrophenyl)methyl]sulfanyl}-4-phenyl-4H-1,2,4-triazole
-
-
3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-(2-fluorobenzylthio)-4-phenyl-4H-1,2,4-triazole
-
-
3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-(2-methylbenzylthio)-4-phenyl-4H-1,2,4-triazole
-
-
3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-(2-nitrobenzylthio)-4-phenyl-4H-1,2,4-triazole
-
-
3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-(3-methoxybenzylthio)-4-phenyl-4H-1,2,4-triazole
-
-
3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-(4-fluorobenzylthio)-4-phenyl-4H-1,2,4-triazole
-
-
3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-5-(4-nitrobenzylthio)-4-phenyl-4H-1,2,4-triazole
-
-
3-(2,4-difluorobenzylthio)-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-phenyl-4H-1,2,4-triazole
-
-
3-(2,6-difluorobenzylthio)-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-phenyl-4H-1,2,4-triazole
-
-
3-(2-bromobenzylthio)-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-phenyl-4H-1,2,4-triazole
-
-
3-(2-chlorobenzylthio)-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-phenyl-4H-1,2,4-triazole
-
-
3-(3-bromobenzylthio)-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-phenyl-4H-1,2,4-triazole
-
-
3-(3-chlorobenzylthio)-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-phenyl-4H-1,2,4-triazole
-
-
3-(4-bromobenzylthio)-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-phenyl-4H-1,2,4-triazole
-
-
3-(4-chlorobenzylthio)-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-phenyl-4H-1,2,4-triazole
-
-
3-(benzoylamino)-N-1,3-thiazol-2-ylpyridine-2-carboxamide
-
wild-type, 50% inhibition above 100 mM, mutant lacking N-terminal 66 amino acids, 50% inhibition at 0.0074 mM
3-(benzylthio)-5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-4-phenyl-4H-1,2,4-triazole
-
-
3-(hexanoylamino)-N-1,3-thiazol-2-ylpyridine-2-carboxamide
-
wild-type, 50% inhibition at 0.0867 mM, mutant lacking N-terminal 66 amino acids, 50% inhibition at 0.0020 mM
3-(pent-4-enoylamino)-N-1,3-thiazol-2-ylpyridine-2-carboxamide
-
wild-type, 50% inhibition above 0.1 mM, mutant lacking N-terminal 66 amino acids, 50% inhibition at 0.00079 mM
3-amino-1-(cyclopropylamino)heptan-2 -one
50% inhibition at 0.007 mM, formation of uncleavable tetrahedral intermediate upon binding
3-But-3-enoylamino-pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50 for Co-EcMetAP1: 0.0001 mM, IC50 for Mn-EcMetAPa: 0.0233 mM, IC50 for Zn-EcMetAP1: 0.0224 mM, IC50 for Ni-EcMetAP1: 0.00076 mM
3-ethyl-2-methoxy-6-[[(2-[[2-(1-methylpyrrolidin-2-yl)ethyl]amino]phenyl)sulfonyl]amino]benzoic acid
-
3-ethyl-2-methoxy-6-[[(2-[[3-(2-methylpiperidin-1-yl)propyl]amino]phenyl)sulfonyl]amino]benzoic acid
-
3-hydroxy-N-1,3-thiazol-2-ylpyridine-2-carboxamide
-
wild-type, 50% inhibition at 0.0081 mM, mutant lacking N-terminal 66 amino acids, 50% inhibition at 0.0035 mM
3-[(phenylsulfonyl)amino]-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid
-
4-((((3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yloxy)carbonylamino)methyl)benzoic acid
-
-
4-(((3-((2-methoxyphenoxy)methyl)-1H-1,2,4-triazol-5-yl)sulfanyl)acetyl)-1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one
-
Co(II)-form of enzyme, 50% inhibition at 0.00099 mM
4-(1-benzyl-1H-1,2,3-triazol-4-yl)benzene-1,2-diol
-
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
4-(1-methyl-1H-imidazol-2-yl)benzene-1,2-diol
-
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
4-(2-aminothiazol-4-yl)benzene-1,2-diol
specific inhibition of Fe2+-loaded MetAP
4-(5-chloro-6-methyl-2-pyridin-2-yl-3,4-dihydropyrimidin-4-yl)morpholine
-
-
4-(5-fluoropyrimidin-2-yl)benzene-1,2-diol
-
does only inhibit Fe2+- or Co2+-activated MetAP enzymes, but not Mn2+-activated MetAP enzyme
4-(5-methoxy-1,3-oxazol-2-yl)benzene-1,2-diol
-
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
4-methyl-2-(1H-1,2,3-triazol-5-yl)pyridine
-
Co(II)-form, Ki,app-value 8 nM, Mn(II)-form, 0.014 mM, 50% reduction of viability of human umbilical vein endothelial cell above 0.03 mM
4-pyridin-2-ylbenzene-1,2-diol
-
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
4-pyrimidin-2-ylbenzene-1,2-diol
-
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
4-[4-(4-methoxyphenyl)piperazin-1-yl]-2-(pyridin-2-yl)quinazoline
EC50 value in presence of Co(II) is 0.0001 mM, superior inhibitory potency and selectivity for isoform MetAP1
5,5'-dithiobis(2-nitrobenzoic acid)
inhibition is through covalent modifiction of residue C105
5,6-dimethyl-2-pyridin-2-yl-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00243 mM
5-((R)-1-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl-pyrrolidin-2-ylmethoxy)-isoquinoline
-
5-(1-benzofuran-2-yl)-1H-1,2,3-triazole
-
Co(II)-form, Ki,app-value 15 nM, Mn(II)-form, 26% inhibition at 0.02 mM, 50% reduction of viability of human umbilical vein endothelial cell at 0.006 mM
5-(2-(trifluoromethyl)phenyl)-2-furoic acid
-
Co(II)-form of enzyme, 50% inhibition at 0.073 mM, Mn(II)-form, 50% inhibition at 0.000063 mM, Ni-(II)form, 50% inhibition above 200 mM, Fe-(II)form, 50% inhibition at 0.195 mM
5-(2-chloro-3-methylphenyl)-2-furoic acid
-
Co(II)-form of enzyme, 50% inhibition at 0.069 mM, Mn(II)-form, 50% inhibition at 0.00096 mM, Ni-(II)form, 50% inhibition above 200 mM, Fe-(II)form, 50% inhibition above 200 mM
5-(2-chlorophenyl)-2-furoic acid
-
Co(II)-form of enzyme, 50% inhibition at 0.154 mM, Mn(II)-form, 50% inhibition at 0.0024 mM, Ni-(II)form, 50% inhibition above 200 mM, Fe-(II)form, 50% inhibition at 0.186 mM
5-(2-fluorophenyl)-2-furoic acid
-
Co(II)-form of enzyme, 50% inhibition at 0.198 mM, Mn(II)-form, 50% inhibition at 0.014 mM, Ni-(II)form, 50% inhibition above 200 mM, Fe-(II)form, 50% inhibition above 200 mM
5-(3,4-dibromophenyl)-1H-1,2,3-triazole
-
Co(II)-form, Ki,app-value 1 nM, Mn(II)-form, 0.016 mM, 50% reduction of viability of human umbilical vein endothelial cell at 0.002 mM
5-(3,4-dihydroxyphenyl)-2-methyl-N-(propan-2-yl)-1,3-thiazole-4-carboxamide
-
-
5-(3,4-dihydroxyphenyl)-N-isopropyl-2-methylthiazole-4-carboxamide
specific inhibition of Fe2+-loaded MetAP
5-(3-chlorophenyl)-2-furoic acid
-
Co(II)-form of enzyme, 50% inhibition at 0.193 mM, Mn(II)-form, 50% inhibition at 0.019 mM, Ni-(II)form, 50% inhibition above 200 mM, Fe-(II)form, 50% inhibition above 200 mM
5-(4-bromophenyl)-1H-1,2,3-triazole
-
Co(II)-form, Ki,app-value 3 nM, Mn(II)-form, 0.011 mM, 50% reduction of viability of human umbilical vein endothelial cell at 0.006 mM
5-(4-chlorophenyl)-1H-1,2,3-triazole
-
Co(II)-form, Ki,app-value 6 nM, Mn(II)-form, 0.011 mM, 50% reduction of viability of human umbilical vein endothelial cell at 0.005 mM
5-(4-iodophenyl)-1H-1,2,3-triazole
-
Co(II)-form, Ki,app-value 1 nM, Mn(II)-form, not inhibitory at 0.02 mM, 50% reduction of viability of human umbilical vein endothelial cell at 0.02 mM
5-(4-methylphenyl)-1H-1,2,3-triazole
-
Co(II)-form, Ki,app-value 15 nM, Mn(II)-form, 4400 nM, 50% reduction of viability of human umbilical vein endothelial cell at 0.03 mM
5-(hydroxymethyl)-1-methoxy-6-[2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]bicyclo[3.1.0]hexan-2-ol
no activity at 0.1 mM
5-chloro-2-(5-chloropyridin-2-yl)-6-methyl-N-((R)-2-phenyl-2-(4-phenylbutylamino)ethyl)pyrimidin-4-amine
compound shows 500fold specificity for isoform AP1 over isoform AP2
5-chloro-2-(5-chloropyridin-2-yl)-N-(2,4-diphenylbutyl)-6-methylpyrimidin-4-amine
compound shows 3175fold specificity for isoform AP1 over isoform AP2
5-chloro-2-pyridin-2-yl-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00169 mM
5-chloro-4-methyl-2-pyridin-2-yl-6-pyrrolidin-1-yl-1,6-dihydropyrimidine
-
-
5-chloro-4-methyl-6-(4-methylbenzyl)-2-pyridin-2-yl-1,6-dihydropyrimidine
-
-
5-chloro-6-(2-ethylphenyl)-4-methyl-2-pyridin-2-yl-1,6-dihydropyrimidine
-
highly selective inhibitor
5-chloro-6-methyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine
-
5-chloro-N,6-dimethyl-N-(2-phenylethyl)-2-pyridin-2-ylpyrimidin-4-amine
-
5-fluoro-2-pyridin-2-yl-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00151 mM
5-methoxy-6-[(4-methoxyphenyl)sulfanyl]-2-pyridin-2-yl-1,6-dihydropyrimidine
-
-
5-methoxy-6-[2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-4-oxobicyclo[3.1.0]hexane-1-carbaldehyde
-
5-methyl-2-((phenylsulfonyl)amino)benzoic acid
50% inhibition of enzyme at 0.0014 mM, 50% inhibition of proliferation of HT-1080 cells at 0.0072 mM
5-methyl-2-(1H-1,2,3-triazol-5-yl)pyridine
-
Co(II)-form, Ki,app-value 3 nM, Mn(II)-form, 0.015 mM, 50% reduction of viability of human umbilical vein endothelial cell at 0.002 mM
5-methyl-2-pyridin-2-yl-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00209 mM
5-nitro-2-pyridin-2-yl-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00016 mM
5-tert-butyl-2-pyridin-2-yl-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00260 mM
5-[(2E)-hepta-2,6-dien-4-yn-1-ylidene]pyrimidine-2,4,6(1H,3H,5H)-trione
-
5-[(3-methylbut-2-en-1-yl)sulfanyl]-N-(2-methylphenyl)-4H-1,2,4-triazol-3-amine
-
5-[(cyclohexylmethyl)sulfanyl]-N-(2-methylphenyl)-4H-1,2,4-triazol-3-amine
-
5-[(cyclohexylmethyl)sulfanyl]-N-(3,4-dimethoxyphenyl)-4H-1,2,4-triazol-3-amine
-
5-[(cyclohexylmethyl)sulfanyl]-N-(4-methoxyphenyl)-4H-1,2,4-triazol-3-amine
-
5-[(cyclohexylmethyl)sulfanyl]-N-(4-methylphenyl)-4H-1,2,4-triazol-3-amine
-
5-[[(2-methyl-2,5-dihydro-1,3-thiazol-4-yl)methyl]sulfanyl]-N-(4-methylphenyl)-4H-1,2,4-triazol-3-amine
-
5-[[(4-chlorophenyl)methyl]sulfanyl]-4H-1,2,4-triazol-3-amine
most potent compound in the host-cell viability assay
5-[[(5-methylisoxazol-3-yl)methyl]sulfanyl]-N-(2-methylphenyl)-4H-1,2,4-triazol-3-amine
-
5-[[(5-methylisoxazol-3-yl)methyl]sulfanyl]-N-(4-methylphenyl)-4H-1,2,4-triazol-3-amine
-
5-[[2-(2-fluorophenyl)ethyl]sulfanyl]-N-(2-methylphenyl)-4H-1,2,4-triazol-3-amine
-
5-[[2-(2-fluorophenyl)ethyl]sulfanyl]-N-(4-methoxyphenyl)-4H-1,2,4-triazol-3-amine
-
5-[[2-(2-fluorophenyl)ethyl]sulfanyl]-N-(4-methylphenyl)-4H-1,2,4-triazol-3-amine
-
5-[[2-(2-methoxyphenyl)ethyl]sulfanyl]-N-(2-methylphenyl)-4H-1,2,4-triazol-3-amine
-
5-[[2-(2-methoxyphenyl)ethyl]sulfanyl]-N-(4-methylphenyl)-4H-1,2,4-triazol-3-amine
-
5-[[2-(3,4-difluorophenyl)ethyl]sulfanyl]-N-(2-methylphenyl)-4H-1,2,4-triazol-3-amine
-
5-[[2-(3,4-difluorophenyl)ethyl]sulfanyl]-N-(3,4-dimethoxyphenyl)-4H-1,2,4-triazol-3-amine
-
5-[[2-(3,4-difluorophenyl)ethyl]sulfanyl]-N-(4-methoxyphenyl)-4H-1,2,4-triazol-3-amine
-
5-[[2-(3,4-difluorophenyl)ethyl]sulfanyl]-N-(4-methylphenyl)-4H-1,2,4-triazol-3-amine
-
6-(1,5-dimethylhex-4-en-1-yl)-5-(hydroxymethyl)-1-methoxybicyclo[3.1.0]hexan-2-one
-
6-(1H-benzimidazol-2-ylamino)pyridin-2-ol
Co(II)-form of enzyme, 50% inhibition at 0.00134 mM
6-(2-chlorobenzyl)-2-pyridin-2-yl-4-(trifluoromethyl)-1,6-dihydropyrimidine
-
-
6-(benzylsulfanyl)-5-chloro-4-methyl-2-pyridin-2-yl-1,6-dihydropyrimidine
-
-
6-(phenylsulfanyl)-2-pyridin-2-yl-4-(trifluoromethyl)-1,6-dihydropyrimidine
-
-
6-[(1E)-1,5-dimethylhexa-1,4-dien-1-yl]-5-(hydroxymethyl)-1-methoxybicyclo[3.1.0]hexan-2-one
-
6-[(2,4-dichlorophenyl)sulfanyl]-5-methoxy-2-pyridin-2-yl-1,6-dihydropyrimidine
-
-
6-[(4-methoxyphenyl)sulfanyl]-2-pyridin-2-yl-4-(trifluoromethyl)-1,6-dihydropyrimidine
-
-
6-[([2-[(1E)-3-(diethylamino)prop-1-en-1-yl]-4-fluorophenyl]sulfonyl)amino]-3-ethyl-2-methoxybenzoic acid
-
6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-2-(1H-imidazol-4-yl)-3-methoxybenzoic acid
-
6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-2-furan-2-yl-3-methoxybenzoic acid
-
6-[[(2-bromo-4-fluorophenyl)sulfonyl]amino]-2-furan-3-yl-3-methoxybenzoic acid
-
6-[[(2-[(1E)-3-(diethylamino)prop-1-en-1-yl]-4-fluorophenyl]sulfonyl)amino]-3-furan-3-yl-2-methoxybenzoic acid
-
6-[[(2-[[3-(dimethylamino)propyl]amino]-4-fluorophenyl)sulfonyl]amino]-3-furan-3-yl-2-methoxybenzoic acid
-
6-[[(2-[[4-(dimethylamino)butyl]amino]phenyl)sulfonyl]amino]-3-ethyl-2-methoxybenzoic acid
-
6-[[(4-fluorophenyl)sulfonyl]amino]-2-(1-hydroxyethyl)-3-methylbenzoic acid
-
6-[[(4-fluorophenyl)sulfonyl]amino]-2-(hydroxymethyl)-3-methylbenzoic acid
-
6-[[(4-fluorophenyl)sulfonyl]amino]-2-methoxy-3-(1H-pyrazol-4-yl)benzoic acid
-
8-pyridin-2-yl-7H-purine
Co(II)-form of enzyme, 50% inhibition at 0.00038 mM
A-310840
-
IC50: 0.000031 mM for enzyme with Zn2+, 0.000043 mM for enzyme with Ni2+, 0.000069 mM for enzyme with Co2+, 0.000026 for enzyme with Fe2+, 0.0578 mM for enzyme with Mn2+
A-311263
-
IC50: 0.000121 mM for enzyme with Zn2+, 0.000107 mM for enzyme with Ni2+, 0.000149 mM for enzyme with Co2+, 0.00011 mM for enzyme with Fe2+, 0.000055 mM for enzyme with Mn2+
bengamide B
nonselective inhibitor for both MetAP1 and MetAP2; nonselective inhibitor for both MetAP1 and MetAP2
bengamide G
nonselective inhibitor for both MetAP1 and MetAP2; nonselective inhibitor for both MetAP1 and MetAP2
bengamide L
nonselective inhibitor for both MetAP1 and MetAP2; nonselective inhibitor for both MetAP1 and MetAP2
bengamide M
nonselective inhibitor for both MetAP1 and MetAP2; nonselective inhibitor for both MetAP1 and MetAP2
bengamide N
nonselective inhibitor for both MetAP1 and MetAP2; nonselective inhibitor for both MetAP1 and MetAP2
bengamide O
nonselective inhibitor for both MetAP1 and MetAP2; nonselective inhibitor for both MetAP1 and MetAP2
cyclopropyl 5-(3,4-dihydroxyphenyl)-2-methyl-1,3-thiazole-4-carboxylate
-
DTNB
-
the enzyme is fully reactivated when incubated with tris(2-carboxyethyl)-phosphine hydrochloride
ethyl (6E)-8-[(2R,3R)-3-[(1S,5S)-5-(hydroxymethyl)-1-methoxy-2-oxobicyclo[3.1.0]hex-6-yl]-3-methyloxiran-2-yl]oct-6-enoate
no activity at 0.1 mM
ethyl 5-(3,4-dihydroxyphenyl)-1,3-oxazole-4-carboxylate
-
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
fumagillol
-
i.e. (3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-ol
isobutyl (2-((1,3-thiazol-2-ylamino)carbonyl)pyridin-3-yl)carbamate
-
wild-type, 50% inhibition above 100 mM, mutant lacking N-terminal 66 amino acids, 50% inhibition above 100 mM
LAF 389
nonselective inhibitor for both MetAP1 and MetAP2; nonselective inhibitor for both MetAP1 and MetAP2
MCB2379
-
IC50: 599 nM in presence of Co2+, 1455 nM in presence of Zn2+
MCB2813
-
IC50: 43.7 nM in presence of Co2+, 300 nM in presence of Zn2+
methionine
feedback inhibition. 70% inhibition at 0.1 mM
methyl 4-([5-[(3-methylbut-2-en-1-yl)sulfanyl]-4H-1,2,4-triazol-3-yl]amino)benzoate
-
methyl 4-([5-[(cyclohexylmethyl)sulfanyl]-4H-1,2,4-triazol-3-yl]amino)benzoate
-
methyl 4-([5-[(pyridin-2-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-yl]amino)benzoate
-
methyl 4-([5-[(pyridin-4-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-yl]amino)benzoate
-
methyl 4-[(5-[[(2-methyl-1,3-thiazolidin-4-yl)methyl]sulfanyl]-4H-1,2,4-triazol-3-yl)amino]benzoate
-
methyl 4-[(5-[[(5-methylisoxazol-3-yl)methyl]sulfanyl]-4H-1,2,4-triazol-3-yl)amino]benzoate
-
methyl 4-[(5-[[2-(2-fluorophenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-yl)amino]benzoate
-
methyl 4-[(5-[[2-(2-methoxyphenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-yl)amino]benzoate
-
methyl 4-[(5-[[2-(2-methylphenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-yl)amino]benzoate
-
methyl 4-[(5-[[2-(3,4-difluorophenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-yl)amino]benzoate
-
methyl N-[(2S,3R)-3-amino-2-hydroxy-3-(4-methylphenyl)propanoyl]-L-alanylleucinate
-
-
methyl N-[(2S,3R)-3-amino-2-hydroxy-3-[4-(1-methylethyl)phenyl]propanoyl]-L-alanylleucinate
-
-
methyl [[(2S)-2-([(2S,3R)-3-amino-2-hydroxy-3-[4-(trifluoromethyl)phenyl]propanoyl]amino)propanoyl]amino]acetate
-
-
N-((R)-2-(5-chloro-2-(5-chloropyridin-2-yl)-6-methylpyrimidin-4-ylamino)-1-phenylethyl)-3-phenylpropanamide
compound shows 323fold specificity for isoform AP1 over isoform AP2
N-(1,3-thiazol-2-yl)-3-[(N-[2-[2-(2-[2-[(1H-triaziren-1-ylacetyl)amino]ethoxy]ethoxy)ethoxy]-4-[3-(trifluoromethyl)-3H-diaziren-3-yl]benzoyl]glycyl)amino]pyridine-2-carboxamide
-
-
N-(2-aminoethyl)-N'-[5-chloro-6-methyl-2-pyridin-2-yl-4-[5-(trifluoromethyl)pyridin-2-yl]-3,4-dihydropyrimidin-4-yl]ethane-1,2-diamine
-
-
N-(2-aminoethyl)-N'-[5-chloro-6-methyl-2-pyridin-3-yl-4-[5-(trifluoromethyl)pyridin-2-yl]-3,4-dihydropyrimidin-4-yl]ethane-1,2-diamine
-
-
N-(2-aminoethyl)-N'-[5-chloro-6-methyl-2-pyridin-4-yl-4-[5-(trifluoromethyl)pyridin-2-yl]-3,4-dihydropyrimidin-4-yl]ethane-1,2-diamine
-
-
N-(2-methylphenyl)-5-[(pyridin-4-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(2-methylphenyl)-5-[[(2-methyl-1,3-thiazolidin-4-yl)methyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(2-methylphenyl)-5-[[2-(2-methylphenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(3,4-dimethoxyphenyl)-5-[(3-methylbut-2-en-1-yl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(3,4-dimethoxyphenyl)-5-[(pyridin-2-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(3,4-dimethoxyphenyl)-5-[(pyridin-4-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(3,4-dimethoxyphenyl)-5-[[(2-methyl-1,3-thiazolidin-4-yl)methyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(3,4-dimethoxyphenyl)-5-[[(5-methylisoxazol-3-yl)methyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(3,4-dimethoxyphenyl)-5-[[2-(2-fluorophenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(3,4-dimethoxyphenyl)-5-[[2-(2-methoxyphenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(3,4-dimethoxyphenyl)-5-[[2-(2-methylphenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4,5-dihydro-1,3-thiazol-2-yl)-3-[(2,2-dimethylpropanoyl)amino]pyridine-2-carboxamide
-
N-(4,5-dihydro-1,3-thiazol-2-yl)-3-[(3-phenylpropanoyl)amino]pyridine-2-carboxamide
-
N-(4,5-dihydro-1,3-thiazol-2-yl)-3-[[(1E)-2-methylpropylidene]amino]pyridine-2-carboxamide
-
N-(4-chlorophenyl)-5-[(3-methylbut-2-en-1-yl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-chlorophenyl)-5-[(cyclohexylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-chlorophenyl)-5-[(pyridin-2-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-chlorophenyl)-5-[(pyridin-4-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-chlorophenyl)-5-[[(2-methyl-1,3-thiazolidin-4-yl)methyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-chlorophenyl)-5-[[(5-methylisoxazol-3-yl)methyl]sulfany]-4H-1,2,4-triazol-3-amine
-
N-(4-chlorophenyl)-5-[[2-(2-fluorophenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-chlorophenyl)-5-[[2-(2-methoxyphenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-chlorophenyl)-5-[[2-(2-methylphenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-methoxyphenyl)-5-[(3-methylbut-2-en-1-yl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-methoxyphenyl)-5-[(pyridin-2-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-methoxyphenyl)-5-[(pyridin-4-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-methoxyphenyl)-5-[[(5-methylisoxazol-3-yl)methyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-methoxyphenyl)-5-[[2-(2-methoxyphenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-methylphenyl)-5-[(pyridin-2-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-methylphenyl)-5-[(pyridin-4-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-methylphenyl)-5-[(thiophen-2-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-methylphenyl)-5-[[(2-methyl-1,3-thiazolidin-4-yl)methyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(4-methylphenyl)-5-[[2-(2-methylphenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-(5-chloroquinolin-8-yl)benzenesulfonamide
Co(II)-form of enzyme, 50% inhibition at 0.00169 mM, Mn(II)-form, 50% inhibition at 0.0185 mM, Fe(II)-form, at 0.0138 mM, Ni(II)-form, at 0.00742 mM, Zn(II)-form, at 0.0113 mM
N-(5-chloroquinolin-8-yl)methanesulfonamide
Co(II)-form of enzyme, 50% inhibition at 0.000154 mM, Mn(II)-form, 50% inhibition at 0.00164 mM, Fe(II)-form, at 0.00393 mM, Ni(II)-form, at 0.000171 mM, Zn(II)-form, at 0.000806 mM; inhibits the Co(II)- and Ni(II)-forms of MetAP potently
N-(5-[[(2-methyl-1,3-thiazolidin-4-yl)methyl]sulfanyl]-4H-1,2,4-triazol-3-yl)pyridin-3-amine
-
N-(5-[[(5-methylisoxazol-3-yl)methyl]sulfanyl]-4H-1,2,4-triazol-3-yl)pyridin-3-amine
-
N-1,3-thiazol-2-yl-1H-benzimidazol-2-amine
Co(II)-form of enzyme, 50% inhibition at 0.00054 mM
N-1,3-thiazol-2-yl-3-(N-[(2-2-[(1H-triaziren-1-ylacetyl)amino]ethoxy]-4-[[3-(trifluoromethyl)-[3H-diaziren-3-yl]phenyl)carbonyl]glycyl]amino)pyridine-2-carboxamide
-
-
N-2-[(3,5-difluorophenyl)acetyl]-N-[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide
N-biphenyl-2-yl-5-[(3,4-difluorobenzyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-biphenyl-2-yl-5-[(3-methylbut-2-en-1-yl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-biphenyl-2-yl-5-[(cyclohexylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-biphenyl-2-yl-5-[(pyridin-4-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-biphenyl-2-yl-5-[[(5-methylisoxazol-3-yl)methyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-but-3-en-1-yl-5-(3,4-dihydroxyphenyl)-1,3-oxazole-4-carboxamide
-
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
N-cyclopentyl-5-(3,4-dihydroxyphenyl)-1,3-oxazole-4-carboxamide
-
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
N-cyclopentyl-N-(thiazol-2-yl)oxalamide
potent and selective inhibitor
N-cyclopropyl-5-(3,4-dihydroxyphenyl)-2-methyl-1,3-thiazole-4-carboxamide
-
-
N-cyclopropyl-5-(3,4-dihydroxyphenyl)furan-2-carboxamide
-
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
N-ethylmaleimide
1 mM, 90% inhibition. Inhibition is through covalent modifiction of residue C105
N-isobutyl-N'-1,3-thiazol-2-ylethanediamide
-
Co(II)-form of enzyme, 50% inhibition at 0.00028 mM, Mn(II)-form, 50% inhibition at 0.108 mM, Ni-(II)form, 50% inhibition at 0.0034 mM, Fe-(II)form, 50% inhibition at 0.118 mM
N-pyrazin-2-yl-1H-benzimidazol-2-amine
Co(II)-form of enzyme, 50% inhibition at 0.0046 mM
N-pyridin-2-yl-1H-benzimidazol-2-amine
Co(II)-form of enzyme, 50% inhibition at 0.00057 mM
N-quinolin-8-ylmethanesulfonamide
Co(II)-form of enzyme, 50% inhibition at 0.000137 mM, Mn(II)-form, 50% inhibition at 0.00214 mM, Fe(II)-form, at 0.00374 mM, Ni(II)-form, at 0.000184 mM, Zn(II)-form, at 0.00111 mM
N-[4-(chloromethyl)phenyl]-5-[[2-(3,4-difluorophenyl)ethyl]sulfanyl]-4H-1,2,4-triazol-3-amine
-
N-[5-[(3,4-difluorobenzyl)sulfanyl]-4H-1,2,4-triazol-3-yl]pyridin-3-amine
-
N-[5-[(cyclohexylmethyl)sulfanyl]-4H-1,2,4-triazol-3-yl]pyridin-3-amine
-
N-[5-[(pyridin-2-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-yl]pyridin-3-amine
-
N-[5-[(pyridin-4-ylmethyl)sulfanyl]-4H-1,2,4-triazol-3-yl]pyridin-3-amine
-
phenyl(2-(1,3-thiazol-4-yl)-1H-benzimidazol-5-yl)methanone
Co(II)-form of enzyme, 50% inhibition at 0.00240 mM
phenyl(2-pyridin-2-yl-1H-benzimidazol-5-yl)methanone
Co(II)-form of enzyme, 50% inhibition at 0.00040 mM
tert-butyl [2-(4,5-dihydro-1,3-thiazol-2-ylcarbamoyl)pyridin-3-yl]carbamate
-
[(1R)-1-carbamoyl-2-methyl-propyl]-carbamic acid-(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro [2.5] oct-6-yl ester
-
PPI-2458, potent irreversible inhibitor
[(1R)-1-carbamoyl-2-methyl-propyl]-carbamic acid-(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester
[(1R)-1-carbamoyl-2-methyl-propyl]-carbamic acid-(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiranyl]-1-oxaspiro(2,5)oct-6-yl ester
((2RS,3R)-3-amino-2-hydroxy-5-ethylthio)pentanoyl-((S)-(-)-(1-naphthyl)ethyl)amide
-
A-311263, the inhibitor has little or no preference for the type of divalent metal ion that occupies the active site of MetAP
((2RS,3R)-3-amino-2-hydroxy-5-ethylthio)pentanoyl-((S)-(-)-(1-naphthyl)ethyl)amide
-
A-311263, the inhibitor has little or no preference for the type of divalent metal ion that occupies the active site of MetAP
(3R)-amino-(2S)-hydroxyheptanoyl-Ala-Leu methyl ester
-
IC50: 0.095 mM
1-(1H-benzimidazol-2-yl)thiourea
Co(II)-form of enzyme, 50% inhibition at 0.0089 mM
1-benzyl-2-(1,3-thiazol-4-yl)-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00046 mM
1-methyl-2-(1,3-thiazol-4-yl)-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00050 mM
2-(1,3-thiazol-4-yl)-1H-benzimidazol-5-amine
Co(II)-form of enzyme, 50% inhibition at 0.00339 mM
3-((2-naphthylmethyl)sulfanyl)-4H-1,2,4-triazole
-
A-310840, the inhibitor binds to the Co2+-loaded enzyme well but is approximately 23fold less potent for Mn2+-loaded MetAP
3-(2,2,2-trifluoroacetylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.000034 mM
3-(2,2,2-trifluoroacetylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00492
3-(2,2-dimethylpropionylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00034 mM; IC50: 0.00054 mM
3-(2,2-dimethylpropionylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
-
3-(2,2-dimethylpropionyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00068 mM
3-(2,2-dimethylpropionyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00078 mM
3-(2-acetyloxybenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0016 mM
3-(2-acetyloxybenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
0.015 mM
3-(2-fluorobenzoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00028 mM
3-(2-fluorobenzoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50 above 0.1 mM
3-(2-fluorobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00083 mM
3-(2-fluorobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.016 mM
3-(2-iodobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0013 mM
3-(2-iodobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00089 mM
3-(2-methoxybenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0017 mM
3-(2-methoxybenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00055 mM
3-(2-methylbut-2-enoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00028 mM
3-(2-methylbut-2-enoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0109 mM
3-(2-methylbut-2-enoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0044 mM
3-(2-methylbut-2-enoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00039 mM
3-(2-nitrobenzoyloxy)pyridine-2-carboxylic acid thiatol-2-ylamide
-
IC50: 0.0021 mM; IC50 above 0.1 mM
3-(2-nitrobenzoyloxy)pyridine-2-carboxylic acid thiatol-2-ylamide
-
-
3-(3-bromo-4-fluorobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0025 mM
3-(3-bromo-4-fluorobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0034 mM
3-(3-fluorobenzoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00071 mM
3-(3-fluorobenzoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50 above 0.1 mM
3-(3-fluorobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.000095 mM
3-(3-fluorobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50 above 0.1 mM
3-(3-methoxy-2-nitrobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0017 mM
3-(3-methoxy-2-nitrobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00302 mM
3-(3-methylbut-2-enoylamino)pyridien-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00022 mM
3-(3-methylbut-2-enoylamino)pyridien-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00077 mM
3-(3-methylbut-2-enoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0026 mM
3-(3-methylbut-2-enoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00049 mM
3-(3-methylbut-3-enoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00015 mM
3-(3-methylbut-3-enoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00467
3-(3-nitrobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0006 mM
3-(3-nitrobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50 above 0.1 mM
3-(4-fluorobenzoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00136 mM
3-(4-fluorobenzoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50 above 0.1 mM
3-(4-fluorobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0011 mM
3-(4-fluorobenzoyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.062 mM
3-(4-methylpent-3-enoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00024 mM
3-(4-methylpent-3-enoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00014 mM
3-(5-methylhex-4-enoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.000671 mM
3-(5-methylhex-4-enoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00031 mM
3-(but-3-enoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00013 mM
3-(but-3-enoylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00038 mM
3-(cyclohexanecarbonylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00087 mM
3-(cyclohexanecarbonylamino)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50 above 0.1 mM
3-(cyclohexanecarbonyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00239 mM
3-(cyclohexanecarbonyloxy)pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00032 mM
3-aminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 1.7 mM, IC50: 0.0328 mM
3-benzoylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00089 mM
3-benzoylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC5ß0 above 0.1 mM
3-benzoyloxypyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00103 mM
3-formylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00033 mM
3-formylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00032
3-hexanoylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.000038 mM
3-hexanoylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00062 mM
3-hexanoyloxypyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00102 mM
3-hexanoyloxypyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.000174 mM
3-hydroxypyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00486 mM
3-iso-butoxycarbonylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00192 mM
3-iso-butoxycarbonylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0537
3-phenylacetylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00004 mM
3-phenylacetylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00082 mM
3-phenylacetyloxypyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.000054 mM
3-phenylacetyloxypyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0002 mM
3-propionylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00026 mM
3-propionylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00035 mM
3-propionyloxypyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0054 mM
3-propionyloxypyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00038 mM
3-tert-butoxycarbonylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00018 mM
3-tert-butoxycarbonylaminopyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.00335 mM
3-[3-(2-methoxyphenyl)acryloyloxy]pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0021 mM
3-[3-(2-methoxyphenyl)acryloyloxy]pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50: 0.0099 mM
4-(1,3-thiazol-2-yl)benzene-1,2-diol
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
4-(2,5-dimethylthiophen-3-yl)benzene-1,2-diol
specific inhibition of Fe2+-loaded MetAP
4-(2-methyl-1,3-thiazol-4-yl)benzene-1,2-diol
-
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
4-(2-methyl-1,3-thiazol-4-yl)benzene-1,2-diol
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
4-(3-methylthiophen-2-yl)benzene-1,2-diol
-
does only inhibit Fe2+-activated MetAP enzyme, but not Mn2+- or Co2+-activated MetAP enzymes
5-(2,5-dichlorophenyl)furan-2-carboxylic acid
potent and selective inhibitor
5-chloro-2-(1,3-thiazol-4-yl)-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00515 mM
5-fluoro-2-(1,3-thiazol-4-yl)-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00431 mM
5-methyl-2-(1,3-thiazol-4-yl)-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00716 mM
5-nitro-2-(1,3-thiazol-4-yl)-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00122 mM
5-tert-butyl-2-(1,3-thiazol-4-yl)-1H-benzimidazole
Co(II)-form of enzyme, 50% inhibition at 0.00391 mM
5-[(2,4-dichlorobenzyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
5-[(2,4-dichlorobenzyl)sulfanyl]-4H-1,2,4-triazol-3-amine
-
5-[2-(trifluoromethyl)phenyl]furan-2-carboxylic acid
potent and selective inhibitor
actinonin
0.01 mM, 40% loss of activity; 0.01 mM, 70% loss of activity
bengamide A
nonselective inhibitor for both MetAP1 and MetAP2; nonselective inhibitor for both MetAP1 and MetAP2
bengamide A
nonspecific, reversible inhibitor of MetAP-1 and MetAP-2; nonspecific, reversible inhibitor of MetAP-1 and MetAP-2
bestatin
0.01 mM, 25% loss of activity; 0.01 mM, 50% loss of activity
Co2+
-
in excess, a third Co2+ ion binds to the active site regions and results in inhibition
EDTA
-
33.7% relative activity at 100 mM, the enzyme activity inhibited by 1 mM EDTA is restored in presence of 5 mM Mg2+
EDTA
1 mM, about 10% residual activity. The aminopeptidase activity of the EDTA-inactivated enzyme is successfully restored by Mn2+
fumagillin
binding structure, overview. Fumagillin and its analogues show inhibitory activity in vitro and in animal models of microsporidiosis and human infections due to Enterocytozoon bieneusi
fumagillin
-
fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase
fumagillin
a covalent bond is formed between a reactive epoxide of fumagillin and histidine-231 in the active site of Met-AP2. Fumagillin-based drugs inhibit MetAP-2 but not MetAP-1
fumagillin
higher affinity to MetAP2 than to MetAP1; lower affinity to MetAP1 than to MetAP2
fumagillin
-
binding structure, specificity determinants lie in the S1 hydrophobic methionine binding subsite, overview
N-(pyridin-2-ylmethyl)-N'-1,3-thiazol-2-ylethanediamide
-
Co(II)-form of enzyme, 50% inhibition at 0.000073 mM, Mn(II)-form, 50% inhibition at 0.043 mM, Ni-(II)form, 50% inhibition at 0.002 mM, Fe-(II)form, 50% inhibition at 0.065 mM
N-(quinolin-8-yl)methanesulfonamide
inhibits the Co(II)- and Ni(II)-forms of MetAP potently
N-(quinolin-8-yl)methanesulfonamide
-
a trimetalated enzyme, forms a complex with the enzyme, cuases bacterial growth inhibition of strains AS19, D22 and SM101 by targeting MetAP by recruitment of a third auxiliary metal, binding structure, overview
N-1,3-thiazol-2-ylpyridine-2-carboxamide
Co(II)-form of enzyme, 50% inhibition at 0.000063 mM, binds to an additional Co2+ ion at the entrance of the active site
N-1,3-thiazol-2-ylpyridine-2-carboxamide
-
wild-type, 50% inhibition at 0.0104 mM, mutant lacking N-terminal 66 amino acids, 50% inhibition at 0.0049 mM
N-1,3-thiazol-2-ylpyridine-2-carboxamide
-
Co(II)-form of enzyme, 50% inhibition at 0.0071 mM
N-2-[(3,5-difluorophenyl)acetyl]-N-[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide
-
N-2-[(3,5-difluorophenyl)acetyl]-N-[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide
-
-
N-2-[(3,5-difluorophenyl)acetyl]-N-[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide
-
-
N-2-[(3,5-difluorophenyl)acetyl]-N-[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide
-
-
N-cyclopentyl-N'-1,3-thiazol-2-ylethanediamide
-
Co(II)-form of enzyme, 50% inhibition at 0.000067 mM, Mn(II)-form, 50% inhibition at 0.053 mM, Ni-(II)form, 50% inhibition at 0.001 mM, Fe-(II)form, 50% inhibition at 0.046 mM
N-cyclopropyl-2-(3,4-dihydroxyphenyl)thiophene-3-carboxamide
specific inhibition of Fe2+-loaded MetAP
ovalicin
-
covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase
ovalicin
higher affinity to MetAP2 than to MetAP1; lower affinity to MetAP1 than to MetAP2
Pyridine-2-carboxylic acid thiazol-2-ylamide
-
IC50 for Co-EcMetAP1: 0.0013 mM
thiabendazole
Co(II)-form of enzyme, 50% inhibition at 0.00047 mM, binds to an additional Co2+ ion at the entrance of the active site
TNP-470
is likely to inhibit the enzyme by occupying the active site in the same fashion as fumagillin
TNP-470
-
binding structure, specificity determinants lie in the S1 hydrophobic methionine binding subsite, overview
TNP-470
treatment inhibits programmed cell death in miltefosine-treated promastigotes. It inhibits the biochemical features of metazoan apoptosis, including caspase3/7 protease like activity, oligonucleosomal DNA fragmentation, collapse of mitochondrial transmembrane potential, and increase in cytosolic pool of calcium ions but does not prevent the cell death and phosphatidyl serine externalization
TNP-470
-
a fumagillin derivative, targets MetAP2, no binding to MetAP1 isozymes
[(1R)-1-carbamoyl-2-methyl-propyl]-carbamic acid-(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester
PPI-2458
[(1R)-1-carbamoyl-2-methyl-propyl]-carbamic acid-(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester
PPI-2458, 5 mg/kg
[(1R)-1-carbamoyl-2-methyl-propyl]-carbamic acid-(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiranyl]-1-oxaspiro(2,5)oct-6-yl ester
-
PPI-2458, potent inhibitor
[(1R)-1-carbamoyl-2-methyl-propyl]-carbamic acid-(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiranyl]-1-oxaspiro(2,5)oct-6-yl ester
-
PPI-2458, potent inhibitor
[(1R)-1-carbamoyl-2-methyl-propyl]-carbamic acid-(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiranyl]-1-oxaspiro(2,5)oct-6-yl ester
-
PPI-2458, potent inhibitor
[amino(cyclohexyl)methyl]phosphonic acid
compound selectively inhibits the Streptococcus pneumoniae MetAP in low micromolar range but not the human enzyme. Residue F309 in the human enzyme and M205 in the Streptococcus pneumoniae MetAP at the analogous position render them with different susceptibilities against the inhibitor
[amino(cyclohexyl)methyl]phosphonic acid
compound selectively inhibits the Streptococcus pneumoniae MetAP in low micromolar range but not the human enzyme. Residue F309 in the human enzyme and M205 in the Streptococcus pneumoniae MetAP at the analogous position render them with different susceptibilities against the inhibitor
additional information
one of the protomeric states of the enzyme is relevant for inhibitor binding, whereas the other is relevant for substrate hydrolysis
-
additional information
thiabendazole and its derivatives are potent inhibitors in vitro, but fail to inhibit in vivo because they bind as Co2+-complexes to H79, thus blocking the active site of enzyme. In the in vitro assay the metal ion concentration is considerably higher than under in vivo conditions
-
additional information
-
thiabendazole and its derivatives are potent inhibitors in vitro, but fail to inhibit in vivo because they bind as Co2+-complexes to H79, thus blocking the active site of enzyme. In the in vitro assay the metal ion concentration is considerably higher than under in vivo conditions
-
additional information
-
inhibitor synthesis, pharmacokinetics, and molecular modelling
-
additional information
identification of inhibitors for human methionine aminopeptidases MetAP1 and MetAP2. 5-chloro-6-methyl-2-pyridin-2-ylpyrimidine is the minimum element for the inhibition of MetAP1, 5'-chloro is the favored substituent on the pyridine ring for the enhanced potency against MetAP1, and long C4 side chains are the essentials for higher Met AP1-selectivity
-
additional information
-
identification of inhibitors for human methionine aminopeptidases MetAP1 and MetAP2. 5-chloro-6-methyl-2-pyridin-2-ylpyrimidine is the minimum element for the inhibition of MetAP1, 5'-chloro is the favored substituent on the pyridine ring for the enhanced potency against MetAP1, and long C4 side chains are the essentials for higher Met AP1-selectivity
-
additional information
-
a set of inhibitors displayed completely different inhibitory profiles on the two mycobacterial MetAPs in both potency and metalloform selectivity
-
additional information
identification of inhibitors with high selectivity toward the Fe(II)-form, the Mn(II)-form, or the Co(II) and Ni(II) forms of the enzyme, respectively, overview. Binding structure of inhibitors in the active site of isozyme MetAP1c, overview
-
additional information
-
identification of inhibitors with high selectivity toward the Fe(II)-form, the Mn(II)-form, or the Co(II) and Ni(II) forms of the enzyme, respectively, overview. Binding structure of inhibitors in the active site of isozyme MetAP1c, overview
-
additional information
-
identification of pyridinyl-pyrimidine inhibitors with selectivity to isozyme MetAP1b before MetAP1a and MetAP1c
-
